Johnson & Johnson $JNJ Shares Bought by Alpha Cubed Investments LLC

Alpha Cubed Investments LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 152,741 shares of the company’s stock after buying an additional 663 shares during the period. Johnson & Johnson accounts for approximately 0.9% of Alpha Cubed Investments LLC’s holdings, making the stock its 29th biggest holding. Alpha Cubed Investments LLC’s holdings in Johnson & Johnson were worth $23,331,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Allworth Financial LP grew its position in Johnson & Johnson by 13.2% during the second quarter. Allworth Financial LP now owns 372,679 shares of the company’s stock valued at $56,927,000 after acquiring an additional 43,358 shares during the period. Addison Advisors LLC lifted its stake in shares of Johnson & Johnson by 10.8% in the 2nd quarter. Addison Advisors LLC now owns 9,791 shares of the company’s stock valued at $1,496,000 after purchasing an additional 955 shares in the last quarter. BOK Financial Private Wealth Inc. grew its holdings in shares of Johnson & Johnson by 51.2% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 13,165 shares of the company’s stock worth $2,011,000 after purchasing an additional 4,457 shares during the period. Altman Advisors Inc. increased its position in Johnson & Johnson by 2.6% during the 2nd quarter. Altman Advisors Inc. now owns 10,619 shares of the company’s stock worth $1,656,000 after purchasing an additional 268 shares in the last quarter. Finally, Compass Capital Management Inc. raised its holdings in Johnson & Johnson by 0.4% in the second quarter. Compass Capital Management Inc. now owns 373,144 shares of the company’s stock valued at $56,998,000 after buying an additional 1,511 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $186.50 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a 50 day simple moving average of $184.25 and a 200-day simple moving average of $168.80. The company has a market capitalization of $449.34 billion, a P/E ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Citigroup increased their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.